Durata Therapeutics today announced the Company initiated a global, pivotal, Phase 3 study of its lead product, dalbavancin, a long-acting, intravenous lipoglycopeptide for the treatment of acute bacterial skin and skin structure infections.
Durata Therapeutics initiates Phase 3 study of dalbavancin for the treatment of acute bacterial skin and skin structure infections